{
    "clinical_study": {
        "@rank": "117801", 
        "arm_group": [
            {
                "arm_group_label": "Febuxostat 40 mg QD", 
                "arm_group_type": "Experimental", 
                "description": "Febuxostat 40 mg, orally, once daily for up to 24 weeks"
            }, 
            {
                "arm_group_label": "Febuxostat 80 mg QD", 
                "arm_group_type": "Experimental", 
                "description": "Febuxostat 80 mg, orally, once daily for up to 24 weeks"
            }, 
            {
                "arm_group_label": "Allopurinol 100mg QD", 
                "arm_group_type": "Active Comparator", 
                "description": "Allopurinol 100mg, orally, three times daily for up to 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare febuxostat allopurinol in subjects with gout."
        }, 
        "brief_title": "Safety and Efficacy of Oral Febuxostat in Subjects With Gout", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Gout", 
        "condition_browse": {
            "mesh_term": "Gout"
        }, 
        "detailed_description": {
            "textblock": "A randomized, double-blind, multicenter, allopurinol-controlled and parallel-assigned study\n      comparing 40 mg, 80 mg of febuxostat, and allopurinol 300 mg in subjects with gout. Subjects\n      will receive treatment for 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hyperuricemia (serum urate \u22658.0 mg/dL) and gout by Chinese Rheumatism Association\n             Criteria;\n\n          -  Renal function defined as a serum creatinine level of < 2.0 mg/dL and creatinine\n             clearance of > 20 milliliters per minute (mL/min) by Cockcroft and Gault formula;\n\n          -  No gout flare 2 weeks beforehand during 2-week screening period.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation;\n\n          -  Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine,\n             thiazide diuretics, or medications containing aspirin (>325 mg) or other salicylates;\n\n          -  Body Mass Index (BMI) >50 kilogram per meter\u00b2(kg/m\u00b2);\n\n          -  A history of active liver disease, or hepatic dysfunction;\n\n          -  A history of bronchial asthma;\n\n          -  A history of renal calculi or thyroid disease;\n\n          -  Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis\n             and bone tumor;\n\n          -  Intolerance to allopurinol and Ibuprofen;\n\n          -  Alcohol intake of \u2265 14 drinks/week;\n\n          -  Clinically significant medical condition."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "522", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082769", 
            "org_study_id": "SFDA2010L04287"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Febuxostat 40 mg QD", 
                    "Febuxostat 80 mg QD"
                ], 
                "intervention_name": "Febuxostat", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Allopurinol 100mg QD", 
                "intervention_name": "Allopurinol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Allopurinol", 
                "Febuxostat"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gout", 
            "Uric Acid", 
            "Xanthine oxidase", 
            "Febuxostat"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout", 
        "other_outcome": {
            "measure": "Percent Change From Baseline in Serum Urate Levels at Final Visit", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Final Visit (up to 28 weeks)"
        }, 
        "overall_official": [
            {
                "affiliation": "The Second Affiliated Hospital of Shantou University Medical College", 
                "last_name": "Shenren Chen, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Qingdao University", 
                "last_name": "Yangang Wang, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The First Hospital of Shanxi Medical University", 
                "last_name": "Xiumei Liu, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Guangxi Medical University", 
                "last_name": "Hong Liu, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Shanghai First People's Hospital", 
                "last_name": "Yongde Peng, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "LanZhou University", 
                "last_name": "Jianqin Wang, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "People's Hospital of Guangxi", 
                "last_name": "Jinying Lin, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Shaanxi Provincial People's Hospital", 
                "last_name": "Haiwang Ji, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "First Hospital of Jilin University", 
                "last_name": "Bin Liu, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tongde Hospital of Zhejiang Province", 
                "last_name": "Ying Lu, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine", 
                "last_name": "Peng Liu, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Luoyang Orthopedic-Traumatological Hospital", 
                "last_name": "Yonghong Zhang, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL)", 
            "safety_issue": "No", 
            "time_frame": "Last 3 visits (any last 3 visits up to week 28)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082769"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit", 
            "safety_issue": "No", 
            "time_frame": "Final Visit (up to 28 weeks)"
        }, 
        "source": "Xijing Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Qingdao Shengbang Pharmaceutical Co., Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}